| | |
Local recurrence
|
Recurrence-free survival
|
|---|
|
Variable
| |
Hazard ratio
|
95% CI
|
p-value
|
Hazard ratio
|
95% CI
|
p-value
|
|
Nottigham grade
|
2 vs. 3
|
0.30
|
0.05–1.81
|
0.43
|
0.67
|
0.24–1.88
|
0.75
|
|
Menopausal status
|
Post vs. pre
|
0.25
|
0.03–2.10
|
0.44
|
1.32
|
0.57–3.06
|
0.81
|
|
LVI
|
No vs. Yes
|
0.69
|
0.15–3.08
|
0.63
|
0.48
|
0.19–1.22
|
0.12
|
|
Pathological nodal status
|
No vs. yes
|
1.33
|
0.16–11.03
|
0.79
|
0.41
|
0.05–3.05
|
0.38
|
|
Tumour size before surgery
| |
1.09
|
0.86–1.38
|
0.47
|
1.24
|
1.08–1.42
|
0.003
|
|
Tumour size at surgery
| |
1.03
|
0.85–1.24
|
0.77
|
1.18
|
1.09–1.29
|
< 0.001
|
|
Miller-Payne score
| |
0.74
|
0.42–1.32
|
0.31
|
0.56
|
0.4–0.8
|
0.001
|
|
Chevallier score
| |
0.96
|
0.46–2.02
|
0.92
|
2.01
|
1.14–3.53
|
0.015
|
|
Standard pathology response
| | | |
0.51
| | |
0.05
|
| |
NR vs. pCR
|
3.98
|
0.36–44.0
| |
13.29
|
1.6–110.5
| |
| |
PR vs. pCR
|
2.07
|
0.24–17.7
| |
7.43
|
0.99–56.1
| |
|
Pretreatment stage group
| | | |
0.51
| | |
0.05
|
| |
II vs. III
|
0.62
|
0.15–2.61
| |
0.41
|
0.17–1.0
| |
- Abbreviations: CI confidence interval, LVI lymphovascular invasion, NR no response, pCR pathological complete response, PR partial response
